Abstract
Retinoic acid (RA) was proposed to increase survival of chemotherapy-treated patients with nucleophosmin-1 (NPM-1c)-mutated acute myeloid leukemia. We reported that, ex vivo, RA triggers NPM-1c degradation, P53 activation and growth arrest. PML organizes domains that control senescence or proteolysis. Here, we demonstrate that PML is required to initiate RA-driven NPM-1c degradation, P53 activation and cell death. Mechanistically, RA enhances PML basal expression through inhibition of activated Pin1, prior to NPM-1c degradation. Such PML induction drives P53 activation, favoring blast response to chemotherapy or arsenic in vivo. This RA/PML/P53 cascade could mechanistically explain RA-facilitated chemotherapy response in patients with NPM-1c mutated acute myeloid leukemia.
Cite
CITATION STYLE
Hleihel, R., Hajj, H. E., Wu, H. C., Berthier, C., Zhu, H. H., Massoud, R., … Bazarbachi, A. (2021). A Pin1/PML/P53 axis activated by retinoic acid in NPM-1c acute myeloid leukemia. Haematologica, 106(12), 3090–3099. https://doi.org/10.3324/haematol.2020.274878
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.